Testing_NN Conditions_NNS for_IN Determination_NP of_IN Minimum_NP Fungicidal_JJ Concentrations_NNS of_IN New_NP and_CC Established_NP Antifungal_NP Agents_NPS for_IN Aspergillus_NP spp._NP :_: NCCLS_NP Collaborative_NP Study_NP Standard_NP conditions_NNS are_VBP not_RB available_JJ for_IN evaluating_VBG the_DT minimum_JJ fungicidal_JJ concentrations_NNS (_( MFCs_NP )_) of_IN antifungal_JJ agents_NNS ._SENT This_DT multicenter_NN collaborative_JJ study_NN investigated_VBD the_DT reproducibility_NN in_IN three_CD laboratories_NNS of_IN itraconazole_NN ,_, posaconazole_NN ,_, ravuconazole_NN ,_, voriconazole_NN ,_, and_CC amphotericin_NP B_NP MFCs_NP for_IN 15_CD selected_JJ isolates_NNS of_IN Aspergillus_NP spp._NP After_IN MIC_JJ determinations_NNS for_IN the_DT 15_CD isolates_NNS in_IN each_DT center_NN by_IN the_DT NCCLS_NP M38-A_NP broth_NN microdilution_NN method_NN with_IN four_CD media_NNS ,_, standard_JJ RPMI_NP 1640_CD (_( RPMI_NP )_) ,_, RPMI_NP with_IN 2_CD %_NN dextrose_NN ,_, antibiotic_JJ medium_NN 3_CD (_( M3_NP )_) ,_, and_CC M3_NP with_IN 2_CD %_NN dextrose_NN ,_, MFCs_NP were_VBD determined_VBN for_IN each_DT isolate-medium-drug_NN combination_NN ._SENT MFCs_NNS were_VBD defined_VBN as_IN the_DT lowest_JJS drug_NN dilutions_NNS that_WDT yielded_VBD <3_JJ colonies_NNS (_( approximately_RB 99_CD to_TO 99.5_CD %_NN killing_VBG activity_NN )_) ._SENT The_DT highest_JJS reproducibility_NN (_( 96_CD to_TO 100_CD %_NN )_) was_VBD for_IN amphotericin_NP B_NP MFCs_NP with_IN the_DT four_CD media_NNS ._SENT Although_IN reproducibility_NN was_VBD more_RBR variable_JJ and_CC medium_JJ dependent_NN for_IN the_DT azoles_NNS (_( 91_CD to_TO 98_CD %_NN )_) ,_, agreement_NN was_VBD good_JJ to_TO excellent_JJ for_IN itraconazole_NN ,_, ravuconazole_NN ,_, and_CC voriconazole_NN MFCs_NNS with_IN RPMI_NP and_CC M3_NP (_( 93_CD to_TO 98_CD %_NN )_) ._SENT For_IN posaconazole_NN ,_, the_DT agreement_NN was_VBD higher_JJR with_IN M3_JJ media_NNS (_( 91_CD to_TO 96_CD %_NN )_) than_IN with_IN RPMI_NP media_NNS (_( 91_CD %_NN )_) ._SENT These_DT data_NNS extend_VBP the_DT refinement_NN of_IN testing_VBG guidelines_NNS for_IN susceptibility_NN testing_NN of_IN Aspergillus_NP spp._NP and_CC warrant_NN consideration_NN for_IN introduction_NN into_IN future_JJ versions_NNS of_IN the_DT M38_NP document_NN ._SENT The_DT role_NN of_IN the_DT MFC_NP under_IN these_DT standardized_JJ testing_NN conditions_NNS as_IN a_DT predictor_NN of_IN clinical_JJ outcome_NN needs_VBZ to_TO be_VB established_VBN in_IN clinical_JJ trials_NNS ._SENT Aspergillus_NN fumigatus_NN and_CC other_JJ Aspergillus_NP spp._NP are_VBP responsible_JJ for_IN the_DT majority_NN (_( 85_CD to_TO 90_CD %_NN )_) of_IN clinical_JJ manifestations_NNS of_IN severe_JJ infections_NNS caused_VBN by_IN the_DT filamentous_JJ fungi_NNS (_( moulds_NNS )_) ,_, especially_RB in_IN the_DT immunocompromised_JJ host_NN ._SENT The_DT increased_VBN incidence_NN of_IN fungal_JJ infections_NNS and_CC the_DT development_NN of_IN new_JJ antifungal_JJ agents_NNS have_VBP underscored_VBN the_DT importance_NN of_IN the_DT laboratory_NN 's_POS role_NN in_IN the_DT selection_NN and_CC monitoring_NN of_IN antifungal_JJ therapy_NN ._SENT The_DT National_NP Committee_NP for_IN Clinical_NP Laboratory_NP Standards_NP (_( NCCLS_NP )_) Subcommittee_NP on_IN Antifungal_JJ Susceptibility_NP Tests_NP has_VBZ developed_VBN a_DT reproducible_JJ reference_NN testing_NN procedure_NN for_IN the_DT antifungal_JJ susceptibility_NN testing_NN of_IN moulds_NNS (_( the_DT M38-A_NP document_NN )_) ._SENT The_DT recommendations_NNS described_VBN in_IN the_DT M38-A_NP document_NN for_IN determination_NN of_IN MICs_NP include_VBP the_DT use_NN of_IN the_DT standard_JJ RPMI_NP 1640_CD broth_NN (_( RPMI_NP )_) ,_, which_WDT contains_VBZ 0.2_CD %_NN dextrose_NN ._SENT However_RB ,_, the_DT document_NN does_VBZ not_RB describe_VB testing_VBG conditions_NNS for_IN determination_NN of_IN minimum_JJ fungicidal_JJ (_( or_CC lethal_JJ )_) concentrations_NNS (_( MFCs_NP )_) ._SENT Whether_IN MICs_NP are_VBP the_DT best_JJS in_IN vitro_NN predictors_NNS of_IN in_IN vivo_JJ or_CC clinical_JJ response_NN to_TO antifungal_JJ therapy_NN is_VBZ uncertain_JJ ._SENT Although_IN standard_JJ conditions_NNS are_VBP not_RB available_JJ for_IN determination_NN of_IN fungicidal_JJ activities_NNS for_IN either_DT yeasts_NNS or_CC moulds_NNS ,_, it_PP has_VBZ been_VBN demonstrated_VBN that_IN MFCs_NP may_MD be_VB better_JJR predictors_NNS than_IN MICs_NP of_IN therapeutic_JJ failure_NN of_IN amphotericin_NP B_NP in_IN trichosporonosis_NN and_CC candidemia_NN ._SENT The_DT fungicidal_JJ activities_NNS of_IN the_DT new_JJ triazoles_NNS have_VBP also_RB been_VBN evaluated_VBN during_IN the_DT last_JJ few_JJ years_NNS by_IN nonstandardized_JJ methods_NNS ._SENT The_DT purpose_NN of_IN this_DT collaborative_JJ study_NN was_VBD to_TO investigate_VB the_DT interlaboratory_JJ reproducibility_NN of_IN MFCs_NP following_VBG determinations_NNS of_IN the_DT MICs_NP of_IN five_CD antifungal_JJ agents_NNS obtained_VBN with_IN four_CD media_NNS for_IN each_DT Aspergillus_NP isolate_NN (_( 15_CD isolates_NNS )_) in_IN three_CD laboratories_NNS ._SENT The_DT drugs_NNS evaluated_VBN were_VBD the_DT conventional_JJ agents_NNS amphotericin_NP B_NP (_( Bristol-Myers_NP Squibb_NP Pharmaceutical_NP Research_NP Institute_NP ,_, Wallingford_NP ,_, Conn._NP )_) and_CC itraconazole_NP (_( Janssen_NP Pharmaceutica_NP ,_, Titusville_NP ,_, N.J._NP )_) and_CC three_CD new_JJ triazoles_NNS :_: voriconazole_NP (_( Pfizer_NP Pharmaceuticals_NP ,_, New_NP York_NP ,_, N.Y._NP )_) ,_, posaconazole_NN (_( Schering-Plough_NP Research_NP Institute_NP ,_, Kenilworth_NP ,_, N.J._NP )_) ,_, and_CC ravuconazole_NN (_( Bristol-Myers_NP Squibb_NP Pharmaceutical_NP Research_NP Institute_NP )_) ._SENT The_DT four_CD media_NNS evaluated_VBN were_VBD (_( i_NP )_) RPMI_NP ,_, (_( ii_NP )_) RPMI_NP with_IN 2_CD %_NN dextrose_NN (_( RPMI-2_NP %_NN )_) ,_, (_( iii_NNS )_) conventional_JJ antibiotic_JJ medium_NN 3_CD (_( M3_NP )_) ,_, and_CC (_( iv_NN )_) antibiotic_JJ medium_NN 3_CD with_IN 2_CD %_NN dextrose_NN (_( M3-2_JJ %_NN )_) ._SENT This_DT study_NN was_VBD conducted_VBN simultaneously_RB with_IN the_DT NCCLS_NP multicenter_NN (_( eight-center_NN )_) study_NN that_IN further_RBR investigated_VBN optimal_JJ testing_NN conditions_NNS for_IN the_DT determination_NN of_IN the_DT MICs_NN of_IN itraconazole_NN and_CC three_CD new_JJ triazoles_NNS for_IN Aspergillus_NP spp._NP ;_: the_DT results_NNS of_IN that_DT study_NN have_VBP been_VBN reported_VBN elsewhere_RB ._SENT Study_NN design_NN ._SENT |_SYM Three_CD laboratories_NNS participated_VBN in_IN this_DT study_NN ,_, and_CC each_DT laboratory_NN received_VBD the_DT same_JJ panel_NN of_IN 15_CD coded_VBD (_( isolates_VBZ 1_CD to_TO 15_CD )_) strains_NNS of_IN Aspergillus_NP spp._NP and_CC two_CD control_NN isolates_NNS ._SENT The_DT MICs_NP of_IN amphotericin_NP B_NP ,_, itraconazole_NN ,_, posaconazole_NN ,_, ravuconazole_NN ,_, and_CC voriconazole_NN for_IN each_DT isolate_NN were_VBD obtained_VBN in_IN each_DT of_IN the_DT three_CD centers_NNS by_IN the_DT broth_NN microdilution_NN method_NN following_VBG a_DT standard_JJ protocol_NN ._SENT The_DT standard_JJ protocol_NN included_VBD the_DT susceptibility_NN testing_NN guidelines_NNS described_VBN in_IN the_DT NCCLS_NP M38-A_NP document_NN for_IN MIC_JJ determination_NN with_IN four_CD different_JJ media_NNS and_CC a_DT detailed_JJ description_NN of_IN the_DT testing_VBG parameters_NNS to_TO be_VB evaluated_VBN for_IN MFC_NP determination_NN ._SENT Following_VBG MIC_JJ determination_NN with_IN the_DT four_CD media_NNS ,_, MFCs_NP were_VBD determined_VBN for_IN each_DT isolate-drug-testing_JJ medium_NN combination_NN in_IN the_DT three_CD centers_NNS ._SENT Isolates_NNS ._SENT |_SYM The_DT set_NN of_IN isolates_NNS evaluated_VBN and_CC the_DT available_JJ in_IN vitro_NN and_CC in_IN vivo_JJ data_NNS are_VBP documented_VBN in_IN Table_NP ._SENT These_DT 15_CD isolates_NNS belonged_VBD to_TO the_DT culture_NN collections_NNS of_IN the_DT University_NP of_IN Manchester_NP ,_, Salford_NP ,_, United_NP Kingdom_NP ;_: the_DT University_NP of_IN Texas_NP ;_: the_DT Medical_NP College_NP of_IN Virginia_NP ;_: the_DT National_NP Cancer_NP Institute_NP ;_: and_CC the_DT University_NP Hospital_NP Nijmegen_NP ,_, Nijmegen_NP ,_, The_DT Netherlands_NPS ._SENT Each_DT isolate_NN was_VBD maintained_VBN as_IN a_DT suspension_NN in_IN water_NN at_IN approximately_RB 25C_JJ until_IN testing_NN was_VBD performed_VBN ._SENT The_DT reference_NN isolate_NN of_IN A._NP flavus_NN ATCC_NP 204304_CD and_CC the_DT quality_NN control_NN strain_NN Candida_NP parapsilosis_NN ATCC_NP 22019_CD were_VBD included_VBN as_IN controls_NNS ._SENT For_IN C._NP parapsilosis_NN ATCC_NP 22019_CD ,_, there_EX are_VBP well-established_JJ microdilution_NN MIC_JJ ranges_NNS of_IN the_DT five_CD agents_NNS evaluated_VBN in_IN this_DT study_NN ._SENT Reference_IN MIC_JJ ranges_NNS also_RB have_VBP been_VBN established_VBN for_IN the_DT isolate_NN of_IN A._NP flavus_NN ATCC_NP 204304_CD based_VBN upon_IN repeated_JJ testing_NN in_IN prior_JJ studies_NNS ;_: values_NNS for_IN amphotericin_NP B_NP and_CC itraconazole_NP are_VBP listed_VBN in_IN the_DT M38-A_NP document_NN ,_, and_CC those_DT for_IN the_DT new_JJ triazoles_NNS have_VBP been_VBN reported_VBN elsewhere_RB ._SENT MIC_JJ ranges_NNS for_IN the_DT quality_NN control_NN and_CC reference_NN isolates_NNS were_VBD within_IN established_JJ values_NNS ._SENT Broth_NN microdilution_NN method_NN (_( M38-A_NP )_) ._SENT |_SYM Standard_NP Excel_NP spreadsheets_NNS were_VBD developed_VBN to_TO serve_VB as_IN recording_NN forms_NNS and_CC to_TO enter_VB and_CC analyze_VB data_NNS ._SENT The_DT standard_JJ protocol_NN supplied_VBN to_TO each_DT laboratory_NN for_IN the_DT broth_NN microdilution_NN method_NN provided_VBD detailed_JJ instructions_NNS concerning_VBG the_DT testing_NN conditions_NNS ._SENT A_DT single_JJ lot_NN of_IN each_DT of_IN the_DT four_CD liquid_JJ medium_NN formulations_NNS was_VBD provided_VBN ,_, ready_JJ to_TO use_VB ,_, to_TO all_DT participants_NNS by_IN Trek_NP Diagnostic_NP Systems_NP Inc._NP (_( Westlake_NP ,_, Ohio_NP )_) ._SENT Each_DT batch_NN of_IN standard_JJ RPMI_NP and_CC RPMI-2_NP %_NN was_VBD supplemented_VBN with_IN 0.3_CD g_NN of_IN l-glutamine_NN per_IN liter_NN and_CC 0.165_CD M_NP MOPS_NP (_( morpholinepropanesulfonic_JJ acid_NN )_) buffer_NN (_( 34.54_CD g/liter_NN )_) to_TO pH_NN 7.0_CD +-_NN 0.1_CD at_IN 35C_JJ and_CC did_VBD not_RB contain_VB sodium_NN bicarbonate_NN ._SENT Neither_DT batch_NN of_IN M3_NP or_CC M3-2_NP %_NN was_VBD buffered_VBN ,_, and_CC the_DT pH_NN of_IN both_DT media_NNS was_VBD 7.0_CD +-_NN 0.1_CD ._SENT The_DT five_CD antifungal_JJ agents_NNS amphotericin_NP B_NP ,_, itraconazole_NN ,_, posaconazole_NN ,_, ravuconazole_NN ,_, and_CC voriconazole_NN were_VBD provided_VBN by_IN the_DT manufacturers_NNS as_IN assay_NN powders_NNS ._SENT Additive_JJ drug_NN dilutions_NNS were_VBD prepared_VBN as_IN described_VBN in_IN the_DT NCCLS_NP M38-A_NP document_NN and_CC in_IN previous_JJ reports_NNS (_( -_: )_) in_IN a_DT central_JJ facility_NN (_( Trek_NP Diagnostic_NP Systems_NPS )_) and_CC shipped_VBN frozen_VBN to_TO each_DT participant_NN ._SENT As_IN recommended_VBN in_IN the_DT M38-A_NP document_NN ,_, stock_NN inoculum_NN suspensions_NNS were_VBD prepared_VBN in_IN sterile_JJ saline_NN (_( provided_VBN by_IN Trek_NP Diagnostic_NP Systems_NPS )_) containing_VBG 1_CD %_NN Tween_NP 80_CD from_IN 7-day-old_JJ colonies_NNS grown_VBN on_IN potato_NN dextrose_NN agar_NN slants_NNS (_( provided_VBN by_IN Remel_NP ,_, Lenexa_NP ,_, Kans_NP ._SENT )_) ._SENT The_DT actual_JJ stock_NN inoculum_NN suspensions_NNS by_IN inoculum_NN quantification_NN ranged_VBD from_IN 0.9_CD x_NN 106_CD to_TO 4.5_CD x_SYM 106_CD CFU/ml_NN for_IN 95_CD %_NN of_IN the_DT inoculum_NN densities_NNS evaluated_VBD ._SENT Low_RB (_( 2.5_CD x_SYM 106_CD CFU/ml_NN )_) and_CC high_JJ (_( 5.9_CD x_SYM 106_CD CFU/ml_NN )_) densities_NNS were_VBD reported_VBN for_IN three_CD isolates_NNS ._SENT On_IN the_DT day_NN of_IN the_DT test_NN ,_, each_DT microdilution_NN well_RB containing_VBG 100_CD mul_NN of_IN the_DT diluted_JJ (_( twofold_JJ )_) drug_NN concentrations_NNS was_VBD inoculated_VBN with_IN 100_CD mul_NN of_IN the_DT diluted_JJ (_( two_CD times_NNS )_) conidial_JJ inoculum_NN suspensions_NNS (_( final_JJ volume_NN in_IN each_DT well_NN ,_, 200_CD mul_NN )_) ._SENT The_DT microdilution_NN trays_NNS were_VBD incubated_VBN at_IN 35C_JJ and_CC examined_VBN after_IN 21_CD to_TO 26_CD ,_, 46_CD to_TO 50_CD ,_, and_CC 70_CD to_TO 74_CD h_NN of_IN incubation_NN ._SENT The_DT MIC_JJ endpoints_NNS were_VBD the_DT lowest_JJS drug_NN concentrations_NNS that_WDT showed_VBD absence_NN of_IN growth_NN or_CC complete_JJ growth_NN inhibition_NN (_( 100_CD %_NN inhibition_NN )_) ._SENT MFC_NP determination_NN ._SENT |_SYM The_NP in_IN vitro_NP fungicidal_JJ activities_NNS (_( MFCs_NP )_) were_VBD determined_VBN for_IN each_DT drug-isolate-medium_NN combination_NN as_IN previously_RB described_VBN ._SENT After_IN 72_CD h_NN of_IN incubation_NN ,_, 20_CD mul_NN was_VBD subcultured_VBN from_IN each_DT well_NN that_WDT showed_VBD complete_JJ inhibition_NN (_( 100_CD %_NN or_CC an_DT optically_RB clear_JJ well_NN )_) ,_, from_IN the_DT last_JJ positive_JJ well_RB (_( growth_NN similar_JJ to_TO that_DT for_IN the_DT growth_NN control_NN well_NN )_) ,_, and_CC from_IN the_DT growth_NN control_NN (_( drug-free_JJ medium_NN )_) onto_IN Sabouraud_NP dextrose_NN agar_NN plates_NNS ;_: the_DT contents_NNS of_IN the_DT wells_NNS were_VBD not_RB agitated_VBN prior_RB to_TO removal_NN of_IN the_DT specified_JJ volumes_NNS ._SENT This_DT step_NN was_VBD performed_VBN by_IN subculturing_VBG either_CC one_CD (_( two_CD laboratories_NNS )_) or_CC more_JJR than_IN one_CD (_( one_CD laboratory_NN )_) 20-mul_JJ volume_NN on_IN each_DT plate_NN ._SENT The_DT plates_NNS were_VBD incubated_VBN at_IN 35C_JJ until_IN growth_NN was_VBD seen_VBN in_IN the_DT growth_NN control_NN subculture_NN (_( usually_RB before_IN 48_CD h_NN )_) ._SENT The_DT MFC_NP was_VBD the_DT lowest_JJS drug_NN concentration_NN that_WDT showed_VBD either_RB no_DT growth_NN or_CC fewer_JJR than_IN three_CD colonies_NNS to_TO obtain_VB approximately_RB 99_CD to_TO 99.5_CD %_NN killing_VBG activity_NN ._SENT Data_NP analysis_NN ._SENT |_SYM Both_DT on-scale_NN and_CC off-scale_JJ MICs_NP and_CC MFCs_NP were_VBD included_VBN in_IN the_DT analysis_NN ._SENT The_DT MICs_NP and_CC MFCs_NP from_IN the_DT three_CD centers_NNS for_IN each_DT drug-isolate-medium_NN combination_NN tested_VBN were_VBD compared_VBN to_TO obtain_VB data_NNS regarding_VBG reproducibility_NN ._SENT As_RB previously_RB analyzed_VBD (_( -_: )_) ,_, values_NNS were_VBD considered_VBN in_IN agreement_NN when_WRB the_DT differences_NNS among_IN the_DT values_NNS were_VBD within_IN three_CD dilutions_NNS (_( three_CD wells_NNS )_) ._SENT A_DT measurement_NN of_IN agreement_NN was_VBD then_RB determined_VBN as_IN the_DT percentage_NN of_IN endpoints_NNS within_IN three_CD dilutions_NNS (_( i.e._FW ,_, 1_CD ,_, 2_CD ,_, and_CC 4_CD mug/ml_NN )_) for_IN each_DT combination_NN of_IN drug_NN ,_, isolate_NN ,_, and_CC medium_NN ._SENT In_IN addition_NN ,_, each_DT MIC_NP was_VBD compared_VBN to_TO its_PP$ corresponding_JJ MFC_NP to_TO assess_VB the_DT differences_NNS between_IN the_DT in_IN vitro_NP fungistatic_JJ and_CC fungicidal_JJ endpoints_NNS obtained_VBN with_IN each_DT medium_NN for_IN each_DT isolate_NN in_IN each_DT laboratory_NN ._SENT TABLE_NN 1_CD |_SYM Selected_JJ isolates_NNS evaluated_VBN in_IN this_DT study_NN Reproducibility_NN of_IN susceptibility_NN endpoints_NNS and_CC detection_NN of_IN in_IN vitro_NN resistance_NN are_VBP the_DT main_JJ concerns_NNS when_WRB establishing_VBG standard_JJ testing_NN guidelines_NNS for_IN an_DT antimicrobial_JJ susceptibility_NN test_NN ._SENT Although_IN a_DT recent_JJ NCCLS_NP collaborative_JJ study_NN optimized_VBD MIC_JJ testing_NN guidelines_NNS for_IN detection_NN of_IN resistance_NN to_TO itraconazole_NN and_CC perhaps_RB to_TO three_CD new_JJ triazoles_NNS in_IN Aspergillus_NP spp._NP ,_, the_DT clinical_JJ relevance_NN of_IN those_DT refined_JJ parameters_NNS has_VBZ yet_RB to_TO be_VB determined_VBN ._SENT Because_IN aspergillosis_NN is_VBZ a_DT severe_JJ and_CC commonly_RB fatal_JJ disease_NN ,_, especially_RB in_IN the_DT deeply_RB immunocompromised_VBN host_NN ,_, an_DT agent_NN with_IN fungicidal_JJ activity_NN has_VBZ therapeutic_JJ advantage_NN over_IN an_DT inhibitory_JJ agent_NN ._SENT The_DT fungicidal_JJ activities_NNS of_IN three_CD new_JJ triazoles_NNS against_IN Aspergillus_NP spp._NP and_CC other_JJ moulds_NNS have_VBP been_VBN evaluated_VBN and_CC compared_VBN to_TO those_DT of_IN amphotericin_NP B_NP and_CC itraconazole_NN ._SENT However_RB ,_, collaborative_JJ studies_NNS have_VBP not_RB been_VBN conducted_VBN to_TO detect_VB optimal_JJ testing_NN parameters_NNS for_IN MFC_NP determination_NN ._SENT Our_PP$ study_NN represents_VBZ the_DT first_JJ interlaboratory_JJ investigation_NN of_IN testing_VBG conditions_NNS for_IN determination_NN of_IN the_DT MFCs_NP of_IN amphotericin_NP B_NP ,_, itraconazole_NN ,_, and_CC three_CD new_JJ triazoles_NNS (_( voriconazole_NN ,_, posaconazole_NN ,_, and_CC ravuconazole_NN )_) for_IN three_CD species_NNS of_IN Aspergillus_NP ._SENT As_RB for_IN any_DT other_JJ antimicrobial_JJ procedure_NN ,_, the_DT issue_NN of_IN reliability_NN should_MD be_VB addressed_VBN first_RB ._SENT Table_NN presents_VBZ the_DT summary_NN of_IN interlaboratory_JJ agreement_NN for_IN MFCs_NP that_WDT were_VBD obtained_VBN with_IN four_CD media_NNS for_IN the_DT 15_CD isolates_NNS of_IN Aspergillus_NP spp._NP stratified_VBD by_IN antifungal_JJ agent_NN ._SENT Excellent_JJ reproducibility_NN (_( 96_CD to_TO 100_CD %_NN )_) was_VBD demonstrated_VBN for_IN amphotericin_NP B_NP MFCs_NP with_IN the_DT four_CD media_NNS ;_: 48_CD %_NN of_IN the_DT values_NNS were_VBD within_IN one_CD dilution_NN ,_, and_CC 20_CD %_NN had_VBD the_DT same_JJ value_NN ._SENT In_IN contrast_NN ,_, for_IN the_DT triazoles_NNS ,_, the_DT reproducibility_NN was_VBD more_RBR variable_JJ and_CC dependent_JJ on_IN the_DT medium_JJ formulation_NN and_CC azole_NN tested_VBD ._SENT Reproducibility_NN was_VBD good_JJ to_TO excellent_JJ (_( 91_CD to_TO 98_CD %_NN )_) with_IN RPMI_NP :_: 51_CD (_( voriconazole_NN )_) to_TO 6.2_CD %_NN (_( ravuconazole_NN )_) of_IN the_DT results_NNS had_VBD the_DT same_JJ value_NN ,_, and_CC 61_CD (_( itraconazole_NN )_) to_TO 29.6_CD %_NN (_( posaconazole_NN )_) were_VBD within_IN one_CD dilution_NN ._SENT Addition_NN of_IN 2_CD %_NN dextrose_NN to_TO either_DT M3_NP or_CC RPMI_NP medium_NN did_VBD not_RB appear_VB to_TO enhance_VB reproducibility_NN ._SENT For_IN MIC_JJ testing_NN ,_, the_DT other_JJ NCCLS_NP study_NN demonstrated_VBD that_IN overall_JJ interlaboratory_JJ reproducibility_NN was_VBD higher_JJR with_IN RPMI_NP than_IN with_IN the_DT other_JJ media_NNS for_IN three_CD of_IN the_DT four_CD triazoles_NNS ._SENT In_IN both_DT studies_NNS ,_, differences_NNS in_IN agreement_NN among_IN the_DT media_NNS were_VBD small_JJ ._SENT The_DT reproducibility_NN of_IN MFC_NP endpoints_NNS was_VBD also_RB evaluated_VBN by_IN repetitive_JJ testing_NN (_( at_IN least_JJS three_CD times_NNS in_IN each_DT laboratory_NN )_) of_IN the_DT control_NN isolate_NN of_IN A._NP flavus_NN ATCC_NP 204304_CD ;_: the_DT MFCs_NP of_IN the_DT five_CD antifungal_JJ agents_NNS for_IN this_DT isolate_NN were_VBD consistently_RB within_IN the_DT expected_VBN three-well_NN range_NN with_IN the_DT four_CD media_NNS ._SENT Table_NN summarizes_VBZ amphotericin_NP B_NP MIC_NP and_CC MFC_NP endpoints_NNS with_IN RPMI_NP and_CC M3_NP ._SENT Our_PP$ amphotericin_NP B_NP values_VBZ with_IN both_DT M3_NP media_NNS were_VBD higher_JJR than_IN those_DT routinely_RB obtained_VBN ._SENT In_IN one_CD of_IN three_CD centers_NNS (_( the_DT University_NP of_IN Texas_NP )_) ,_, ranges_VBZ for_IN the_DT MIC_NP and_CC the_DT MIC_NN at_IN which_WDT 50_CD %_NN of_IN the_DT isolates_NNS tested_VBN are_VBP inhibited_VBN (_( MIC50_NP )_) of_IN 0.5_CD to_TO 8_CD and_CC 1_CD to_TO 2_CD mug/ml_NN ,_, respectively_RB ,_, have_VBP been_VBN obtained_VBN with_IN M3_NP broth_NN for_IN 759_CD isolates_NNS of_IN these_DT three_CD species_NNS (_( with_IN MICs_NP above_IN 2_CD mug/ml_NN only_RB for_IN 21_CD Aspergillus_NP terreus_NNS and_CC 3_CD Aspergillus_NP flavus_NN isolates_NNS )_) ._SENT The_DT reasons_NNS for_IN this_DT discrepancy_NN may_MD be_VB the_DT variability_NN among_IN M3_NP lots_NNS that_WDT has_VBZ been_VBN reported_VBN when_WRB testing_VBG Candida_NP spp._NP ._SENT As_IN previously_RB reported_VBN ,_, amphotericin_NP B_NP MICs_NP and_CC MFCs_NP were_VBD usually_RB the_DT same_JJ or_CC the_DT MFCs_NP were_VBD no_RB more_JJR than_IN one_CD to_TO two_CD dilutions_NNS higher_JJR than_IN the_DT corresponding_JJ MICs_NN for_IN A._NP fumigatus_NP and_CC A._NP flavus_NN ._SENT Our_PP$ amphotericin_NP B_NP MIC_NP and_CC MFC_NP ranges_NNS were_VBD narrow_JJ ,_, which_WDT is_VBZ also_RB one_CD of_IN the_DT disadvantages_NNS of_IN amphotericin_NP B_NP MICs_NP for_IN Candida_NP spp._NP Although_IN amphotericin_NP B_NP MICs_NP had_VBD a_DT relatively_RB wide_JJ range_NN (_( 1_CD and_CC 2_CD to_TO >8_JJ mug/ml_NN )_) with_IN M3_JJ media_NNS for_IN A._NP fumigatus_NN ,_, most_JJS values_NNS were_VBD >2_JJ mug/ml_NN or_CC beyond_IN safe_JJ concentrations_NNS in_IN serum_NN achieved_VBN with_IN this_DT agent_NN ._SENT Peak_NN levels_NNS in_IN plasma_NN that_WDT were_VBD below_IN the_DT MIC_NP and_CC MFC_NP results_NNS in_IN this_DT study_NN correlated_VBN with_IN in_IN vivo_JJ response_NN in_IN experimental_JJ pulmonary_JJ aspergillosis_NN caused_VBN by_IN isolate_NN 8_CD ._SENT This_DT response_NN was_VBD directly_RB related_VBN to_TO reduced_VBN tissue_NN burden_NN (_( measured_VBN in_IN log_NN CFU_NP per_IN gram_NN )_) in_IN the_DT lungs_NNS ._SENT Lack_NN of_IN correlation_NN of_IN in_IN vitro_NN results_NNS with_IN in_IN vivo_JJ response_NN has_VBZ been_VBN reported_VBN in_IN a_DT murine_JJ model_NN of_IN invasive_JJ A._NP fumigatus_NN infection_NN when_WRB the_DT animals_NNS were_VBD infected_VBN with_IN isolate_NN 4_CD ;_: this_DT isolate_NN was_VBD recovered_VBN from_IN a_DT patient_NN who_WP responded_VBD incompletely_RB to_TO high-dose_NN amphotericin_NP B_NP ._SENT In_IN the_DT present_JJ study_NN ,_, both_DT media_NNS were_VBD unable_JJ to_TO distinguish_VB this_DT isolate_NN from_IN the_DT others_NNS ._SENT Both_DT RPMI_NP broths_NNS yielded_VBD two_CD distinct_JJ amphotericin_NP B_NP fungicidal_JJ levels_NNS for_IN the_DT three_CD A._NP terreus_NN isolates_NNS ,_, while_IN with_IN M3_NP ,_, the_DT results_NNS were_VBD uniformly_RB high_JJ for_IN all_DT isolates_NNS ._SENT Sutton_NP et_FW al._FW have_VBP demonstrated_VBN the_DT potential_JJ discriminatory_JJ value_NN of_IN amphotericin_NP B_NP MFCs_NP for_IN A._NP terreus_NN with_IN M3_NP broth_NN ,_, and_CC amphotericin_NP B_NP inhibitory_JJ activity_NN was_VBD found_VBN to_TO be_VB superior_JJ (_( geometric_JJ mean_NN MICs_NP ,_, 1.7_CD and_CC 3.37_CD mug/ml_NN )_) to_TO its_PP$ fungicidal_JJ activity_NN (_( geometric_JJ mean_NN MFCs_NP ,_, 7.4_CD and_CC 13.4_CD mug/ml_NN )_) for_IN this_DT species_NN in_IN two_CD studies_NNS ._SENT Because_IN M3_NP is_VBZ widely_RB used_VBN for_IN testing_VBG amphotericin_NP B_NP ,_, it_PP is_VBZ important_JJ that_IN laboratory_NN personnel_NNS be_VB aware_JJ of_IN the_DT problem_NN posed_VBN by_IN M3_NP lot_NN variability_NN as_IN demonstrated_VBN in_IN this_DT study_NN for_IN Aspergillus_NP testing_NN ._SENT In_IN our_PP$ study_NN ,_, amphotericin_NP B_NP had_VBD fungistatic_JJ activity_NN beyond_IN safely_RB achievable_JJ concentrations_NNS in_IN serum_NN for_IN two_CD isolates_NNS (_( modal_JJ MFC_NP ,_, 4_CD mug/ml_NN )_) ,_, while_IN the_DT MFCs_NP (_( 1_CD to_TO 2_CD mug/ml_NN )_) for_IN the_DT third_JJ isolate_NN were_VBD within_IN safely_RB achievable_JJ levels_NNS in_IN serum_NN when_WRB tested_VBN with_IN RPMI_NP ._SENT Although_IN amphotericin_NP B_NP had_VBD the_DT same_JJ inhibitory_JJ activity_NN for_IN all_DT three_CD isolates_NNS (_( MIC_JJ range_NN ,_, 0.5_CD to_TO 2_CD mug/ml_NN )_) ,_, it_PP had_VBD fungicidal_JJ activity_NN for_IN only_RB one_CD ._SENT It_PP is_VBZ noteworthy_JJ that_IN the_DT E-test_NN can_MD also_RB yield_VB distinctive_JJ data_NNS for_IN these_DT three_CD isolates_NNS (_( 0.5_CD to_TO 1_CD and_CC 4_CD mug/ml_NN )_) ._SENT Table_NN summarizes_VBZ azole_NN MFCs_NP and_CC MICs_NP that_WDT were_VBD obtained_VBN with_IN RPMI_NP and_CC M3_NP media_NNS for_IN the_DT 15_CD isolates_NNS stratified_VBN by_IN species_NNS and_CC according_VBG to_TO established_JJ azole_NN susceptibilities_NNS ._SENT The_DT MFC_NP data_NNS with_IN RPMI-2_NP %_NN and_CC M3-2_JJ %_NN were_VBD similar_JJ (_( data_NNS not_RB listed_VBN in_IN Table_NP )_) ._SENT The_DT MFCs_NP of_IN most_JJS triazoles_NNS were_VBD consistently_RB higher_JJR (_( one_CD to_TO four_CD dilutions_NNS )_) than_IN the_DT corresponding_JJ MICs_NN for_IN A._NP fumigatus_NP and_CC A._NP terreus_NN isolates_VBZ with_IN RPMI_NP media_NNS ._SENT In_IN two_CD previous_JJ studies_NNS with_IN larger_JJR numbers_NNS of_IN isolates_NNS ,_, a_DT substantial_JJ difference_NN was_VBD found_VBN between_IN voriconazole_NP MICs_NP (_( geometric_JJ means_NNS ,_, 0.22_CD and_CC 0.63_CD mug/ml_NN )_) and_CC MFCs_NP (_( geometric_JJ means_NNS ,_, 17.4_CD and_CC 6.8_CD mug/ml_NN )_) for_IN A._NP terreus_NN ._SENT Differences_NNS between_IN MICs_NP and_CC MFCs_NP for_IN the_DT three_CD isolates_NNS of_IN A._NP terreus_NNS were_VBD less_RBR pronounced_VBN in_IN this_DT study_NN ._SENT It_PP has_VBZ been_VBN reported_VBN that_IN voriconazole_NP MICs_NP and_CC MFCs_NP were_VBD comparable_JJ for_IN A._NP fumigatus_NP and_CC A._NP flavus_NN (_( MIC90s_NP of_IN 0.5_CD to_TO 1.0_CD mug/ml_NN versus_IN MFCs_NP at_IN which_WDT 90_CD %_NN of_IN isolates_NNS are_VBP killed_VBN [_SYM MFC90s_NP ]_SYM of_IN 0.5_CD to_TO 2_CD mug/ml_NN )_) ,_, while_IN itraconazole_NN MFCs_NP for_IN A._NP fumigatus_NN tended_VBD to_TO be_VB three_CD to_TO four_CD dilutions_NNS higher_JJR than_IN MICs_NP (_( MIC90s_NP of_IN 0.5_CD mug/ml_NN versus_IN MFC90s_NP of_IN 4_CD mug/ml_NN )_) ._SENT The_DT differences_NNS between_IN fungicidal_JJ and_CC fungistatic_JJ activities_NNS of_IN the_DT four_CD triazoles_NNS against_IN A._NP flavus_NN were_VBD less_RBR substantial_JJ :_: 4.2_CD to_TO 8.3_CD %_NN of_IN MFCs_NP were_VBD more_JJR than_IN two_CD dilutions_NNS higher_JJR than_IN MICs_NP ,_, and_CC 17_CD to_TO 33_CD %_NN of_IN MFCs_NP for_IN the_DT other_JJ species_NNS were_VBD higher_JJR ._SENT Fungicidal_JJ data_NNS for_IN posaconazole_NN and_CC ravuconazole_NN are_VBP more_RBR scarce_JJ ._SENT Our_PP$ results_NNS confirm_VBP previous_JJ reports_NNS in_IN which_WDT posaconazole_NN in_IN vitro_NN fungicidal_JJ and_CC fungistatic_JJ activities_NNS appeared_VBD to_TO be_VB superior_JJ to_TO those_DT of_IN the_DT other_JJ triazoles_NNS ._SENT Posaconazole_NP MICs_NP and_CC MFCs_NP were_VBD higher_JJR for_IN the_DT two_CD itraconazole-resistant_JJ isolates_NNS than_IN those_DT for_IN most_JJS of_IN the_DT other_JJ isolates_NNS ._SENT In_IN a_DT temporarily_RB neutropenic_JJ model_NN of_IN invasive_JJ aspergillosis_NN ,_, there_EX was_VBD an_DT similar100-fold_NN difference_NN between_IN the_DT fungal_JJ counts_NNS in_IN lungs_NNS and_CC kidneys_NNS of_IN animals_NNS infected_VBN with_IN isolate_NN 5_CD (_( Tables_NP and_NP )_) and_CC those_DT in_IN animals_NNS infected_VBN with_IN isolate_NN 3_CD with_IN a_DT lower_JJR MIC_NN (_( 0.01_CD mug/ml_NN )_) ._SENT Although_IN these_DT results_NNS suggest_VBP that_IN posaconazole_NN MICs_NNS of_IN >=0.5_JJ mug/ml_NN may_MD indicate_VB potential_JJ in_IN vitro_NN resistance_NN to_TO this_DT agent_NN ,_, the_DT MFCs_NP for_IN these_DT isolates_NNS were_VBD similar_JJ ._SENT Ravuconazole_NP MFCs_NP with_IN RPMI_NP for_IN isolates_NNS 5_CD and_CC 6_CD indicated_VBD that_IN that_DT agent_NN had_VBD similar_JJ fungicidal_JJ activities_NNS for_IN these_DT isolates_NNS but_CC different_JJ fungistatic_JJ activities_NNS ._SENT The_DT clinical_JJ significance_NN of_IN these_DT discrepant_JJ results_NNS has_VBZ yet_RB to_TO be_VB determined_VBN ._SENT In_IN conclusion_NN ,_, because_IN standard_JJ RPMI_NP is_VBZ a_DT chemically_RB defined_VBN medium_NN and_CC MFC_NP reproducibility_NN is_VBZ good_JJ to_TO excellent_JJ for_IN the_DT five_CD agents_NNS ,_, RPMI_NP appears_VBZ to_TO be_VB a_DT suitable_JJ testing_NN medium_NN for_IN determination_NN of_IN fungicidal_JJ susceptibilities_NNS of_IN Aspergillus_NP spp._NP to_TO these_DT five_CD agents_NNS ._SENT Although_IN the_DT reproducibility_NN of_IN M3_NP medium_NN was_VBD similar_JJ to_TO that_DT of_IN RPMI_NP ,_, its_PP$ use_NN is_VBZ limited_VBN until_IN the_DT problem_NN of_IN lot-to-lot_NN variation_NN is_VBZ investigated_VBN and_CC resolved_VBN ._SENT The_DT results_NNS of_IN this_DT NCCLS_NP collaborative_JJ study_NN extend_VB the_DT refinement_NN of_IN testing_VBG conditions_NNS for_IN susceptibility_NN testing_NN of_IN Aspergillus_NP spp._NP to_TO amphotericin_NP B_NP and_CC four_CD triazoles_NNS ._SENT However_RB ,_, the_DT role_NN of_IN the_DT MFC_NP as_IN a_DT predictor_NN of_IN clinical_JJ outcome_NN for_IN Aspergillus_NP spp._NP by_IN following_VBG this_DT standardized_JJ procedure_NN should_MD be_VB established_VBN in_IN either_DT clinical_JJ trials_NNS or_CC experimental_JJ infections_NNS ._SENT The_DT introduction_NN of_IN these_DT optimal_JJ testing_NN conditions_NNS for_IN MFC_NP determination_NN in_IN a_DT more_RBR advanced_JJ version_NN of_IN the_DT NCCLS_NP M38_NP document_NN is_VBZ warranted_VBN ._SENT TABLE_NN 2_CD |_SYM Interlaboratory_JJ agreement_NN of_IN azole_NN and_CC amphotericin_NP B_NP MFCs_NP for_IN 15_CD Aspergillus_NP isolates_NNS in_IN three_CD laboratories_NNS TABLE_NP 3_CD |_SYM Amphotericin_NP B_NP MFCs_NP and_CC MICs_NP for_IN 15_CD Aspergillus_NP isolates_NNS in_IN three_CD laboratories_NNS TABLE_NP 4_CD |_SYM Azole_NP MFCs_NP and_CC MICs_NP for_IN 15_CD Aspergillus_NP isolates_NNS in_IN three_CD laboratories_NNS 